To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...

Oya Gilbert, a 55-year-old who was diagnosed with multiple myeloma in 2017, encourages newly diagnosed patients, especially ...

Estimates based on the most recent data from the NCI's Surveillance, Epidemiology, and End Results (SEER) program show that ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting ...

Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of trials, with results so far showing activity in relapsed or refractory ...

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and ...

Oncopeptides has announced new research demonstrating that its multiple myeloma drug Pepaxti (melflufen) maintains strong anti-myeloma activity in patients with high-risk genetic abnormalities such as ...

Patients share their unexpected journeys with multiple myeloma, revealing challenges and resilience in the face of a cancer ...

Smoldering multiple myeloma (SMM) is an early precursor to a rare blood cancer known as multiple myeloma, which affects plasma cells. This type of cancer produces certain proteins that can be measured ...